RHUMBLINE ADVISERS - APELLIS PHARMACEUTICALS INC ownership

APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 209 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.4%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of APELLIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$5,032,421
-58.4%
132,294
-0.4%
0.01%
-57.1%
Q2 2023$12,104,730
+140033.5%
132,873
+1.5%
0.01%
+27.3%
Q1 2023$8,638
+27.9%
130,961
+0.3%
0.01%
+22.2%
Q4 2022$6,753
-99.9%
130,601
+6.0%
0.01%
-30.8%
Q3 2022$8,414,000
+69.3%
123,189
+12.1%
0.01%
+85.7%
Q2 2022$4,971,000
+25.8%
109,933
+41.4%
0.01%
+40.0%
Q1 2022$3,951,000
+13.0%
77,764
+5.2%
0.01%
+25.0%
Q4 2021$3,495,000
+52.8%
73,929
+6.5%
0.00%
+33.3%
Q3 2021$2,287,000
-45.9%
69,395
+3.8%
0.00%
-50.0%
Q2 2021$4,226,000
+51.9%
66,869
+3.1%
0.01%
+50.0%
Q1 2021$2,782,000
-34.7%
64,832
-13.0%
0.00%
-33.3%
Q4 2020$4,262,000
+90.4%
74,511
+0.4%
0.01%
+50.0%
Q3 2020$2,239,000
-24.2%
74,199
-18.0%
0.00%
-20.0%
Q2 2020$2,954,000
+42.4%
90,436
+16.8%
0.01%
+25.0%
Q1 2020$2,074,000
+3.8%
77,433
+18.7%
0.00%
+33.3%
Q4 2019$1,998,000
+33.0%
65,248
+4.7%
0.00%0.0%
Q3 2019$1,502,000
-4.5%
62,348
+0.5%
0.00%0.0%
Q2 2019$1,572,000
+73.7%
62,050
+33.7%
0.00%
+50.0%
Q1 2019$905,000
+46.0%
46,401
-1.4%
0.00%
+100.0%
Q4 2018$620,000
+9.5%
47,040
+47.9%
0.00%0.0%
Q3 2018$566,000
-24.2%
31,815
-6.3%
0.00%
-50.0%
Q2 2018$747,000
+262.6%
33,952
+264.8%
0.00%
Q1 2018$206,0009,3070.00%
Other shareholders
APELLIS PHARMACEUTICALS INC shareholders Q2 2021
NameSharesValueWeighting ↓
AJU IB Investment Co., Ltd. 1,114,962$63,776,00024.13%
Octagon Capital Advisors LP 548,374$31,367,00010.87%
Ghost Tree Capital, LLC 325,000$18,590,0004.14%
Burrage Capital Management LLC 81,357$4,654,0003.55%
Aufman Associates Inc 53,642$3,068,0002.75%
ACUTA CAPITAL PARTNERS, LLC 167,054$9,555,0002.60%
Cormorant Asset Management, LP 1,866,108$106,741,0002.54%
Tri Locum Partners LP 121,409$6,945,0002.52%
venBio Partners LLC 490,471$28,055,0002.48%
HHLR ADVISORS, LTD. 5,028,289$287,618,0002.29%
View complete list of APELLIS PHARMACEUTICALS INC shareholders